The size of the Middle East and Africa Electrophoresis Market was worth USD 0.20 billion in 2024 and growing at a CAGR of 4.86%, to reach USD 0.25 billion by 2029.
The increased prevalence of cancer, infectious illnesses, and genetic abnormalities has increased funding for genomic, proteomic, and electrophoresis research. In addition, the usage of capillary electrophoresis with mass spectroscopy is growing as the number of industry-academic research collaborations grows. The expansion of clinical, forensic, and research laboratories and the increasing usage of next-generation sequencing is propelling the MEA electrophoresis market forward.
The use of capillary electrophoresis in applications like microbial identification and protein analysis increases its appeal and propels the industry forward. The market is likely to grow substantially in the following years due to the factors mentioned above. In addition, the market for electrophoresis in the Middle East and Africa is growing due to increased usage of next-generation sequencing, industry-academic cooperation, and increased government support for electrophoresis research.
In discovering efficient medicines, the electrophoresis technique has been used to separate DNA, RNA, and protein molecules based on their size. In addition, increased financing for genomic and proteomic research, rising frequency of chronic diseases, increased cooperation between business and academia, and technological advancements are all boosting the electrophoresis market.
Overuse of time and resources in the process is also a barrier to market expansion. Alternative techniques and technologies are also functioning as a market restraint due to their presence or availability. Despite technological breakthroughs in the procedure, an external power supply is still required to operate the electrophoresis. Because electrophoresis can only be used in a room with an external power supply, this is a bottleneck for any electrophoresis system. The effect of contaminations such as selenium and vanadium, which might affect gel results, is another downside of currently available electrophoresis equipment and methodologies. Finally, the high cost is the main barrier to introducing the infrastructure and methods in remote areas.
In the Middle East and Africa region, there is a rise in prostates, breast, and cervical cancer cases. The rising prevalence of these diseases is driving the need for innovative diagnostic processes and the development of novel therapeutic drugs, propelling the electrophoresis market forward.
In worldwide marketplaces, the Middle East and Africa area have a moderate share. However, academic and research institutions and pharmaceutical and biotechnology firms have increased their research operations in the rising economies of the UAE and Kuwait. Some of the important factors driving the market expansion in the Middle East and Africa are improved technology usage and rising health awareness.
The researchers devised a new approach for identifying single virus particles based on electrophoresis variations in electrical current. In addition, the researchers devised a new approach for doing quick and accurate screening tests for infections such as influenza.
The fast-developing healthcare infrastructure and inexpensive labor costs in rising Middle Eastern countries also contribute to strong growth in the UAE and Kuwait. However, chronic diseases such as cardiovascular disease, chronic lung disease, diabetes, and cancer were the leading causes of death in the Middle East and Africa region, according to the World Health Organization (WHO), claiming an estimated 8.5 million lives per year.
As a result, factors such as rising per capita income and increased public healthcare spending are likely to support the electrophoresis market's expansion over the forecast period.
A few of the noteworthy companies operating in the Middle East & Africa electrophoresis market profiled in the report are Bio-Rad Laboratories, GE Healthcare, Thermo Fisher Scientific Inc, Danaher Corporation, Agilent Technologies, Merck Millipore, PerkinElmer, QIAGEN N.V., Lonza Group Ltd., Shimadzu Corporation, Harvard Bioscience, Sebia Group, and C.B.S. Scientific Company.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1600
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region